NO2209805T3 - - Google Patents

Info

Publication number
NO2209805T3
NO2209805T3 NO08844563A NO08844563A NO2209805T3 NO 2209805 T3 NO2209805 T3 NO 2209805T3 NO 08844563 A NO08844563 A NO 08844563A NO 08844563 A NO08844563 A NO 08844563A NO 2209805 T3 NO2209805 T3 NO 2209805T3
Authority
NO
Norway
Application number
NO08844563A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2209805T3 publication Critical patent/NO2209805T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NO08844563A 2007-10-30 2008-10-27 NO2209805T3 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98360607P 2007-10-30 2007-10-30
PCT/EP2008/009070 WO2009056268A1 (en) 2007-10-30 2008-10-27 An antigen associated with rheumatoid arthritis

Publications (1)

Publication Number Publication Date
NO2209805T3 true NO2209805T3 (cg-RX-API-DMAC7.html) 2018-02-03

Family

ID=40282320

Family Applications (1)

Application Number Title Priority Date Filing Date
NO08844563A NO2209805T3 (cg-RX-API-DMAC7.html) 2007-10-30 2008-10-27

Country Status (18)

Country Link
US (4) US8222377B2 (cg-RX-API-DMAC7.html)
EP (3) EP2209805B1 (cg-RX-API-DMAC7.html)
JP (3) JP5106635B2 (cg-RX-API-DMAC7.html)
KR (3) KR101836968B1 (cg-RX-API-DMAC7.html)
CN (2) CN101918443B (cg-RX-API-DMAC7.html)
AU (1) AU2008317941B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0818272B8 (cg-RX-API-DMAC7.html)
CA (1) CA2704296C (cg-RX-API-DMAC7.html)
DK (2) DK2209805T3 (cg-RX-API-DMAC7.html)
ES (2) ES2807753T3 (cg-RX-API-DMAC7.html)
HU (2) HUE050038T2 (cg-RX-API-DMAC7.html)
MX (1) MX2010004726A (cg-RX-API-DMAC7.html)
NO (1) NO2209805T3 (cg-RX-API-DMAC7.html)
PL (2) PL3281952T3 (cg-RX-API-DMAC7.html)
PT (2) PT3281952T (cg-RX-API-DMAC7.html)
RU (2) RU2486198C2 (cg-RX-API-DMAC7.html)
SI (2) SI3281952T1 (cg-RX-API-DMAC7.html)
WO (1) WO2009056268A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070084556A1 (en) 2005-10-14 2007-04-19 Langseder Neal E Method of applying a label to a squeeze tube
EA036322B1 (ru) 2007-04-02 2020-10-26 Филоджен С.П.А. Антитело, связывающееся с изоформой ed-a фибронектина, и его применение для лечения опухолевых метастазов
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
PT3281952T (pt) 2007-10-30 2020-07-23 Philogen Spa Um antigénio associado a artrite reumatoide
ES2549362T3 (es) 2009-01-07 2015-10-27 Philogen S.P.A. Antígenos asociados a endometriosis
US8679488B2 (en) 2009-08-05 2014-03-25 Philogen S.P.A. Targeting of bone marrow neovasculature
ES2706428T3 (es) * 2011-07-27 2019-03-28 Philogen Spa Inmunoconjugado de IL-12
CN104540848B (zh) * 2012-08-08 2019-05-31 罗切格利卡特公司 白介素-10融合蛋白及其用途
TWI499426B (zh) * 2012-09-27 2015-09-11 Philogen Spa 與發炎性腸病有關之抗原
PT2903629T (pt) 2012-10-03 2019-09-10 Philogen Spa Conjugado de anticorpo para utilização no tratamento de uma doença inflamatória do intestino
CA2935665A1 (en) * 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukine 10 immunoconjugates
GB201507908D0 (en) 2015-05-08 2015-06-24 Philogen Spa IL2 and TNF immunoconjugates
RU2018105687A (ru) 2015-07-16 2019-08-16 Филоджен С.П.А. Иммуноконъюгаты на основе il22
US20190309060A1 (en) 2016-01-15 2019-10-10 Philogen S.P.A. Intestinal antigens for pharmacodelivery applications
JP2017197558A (ja) * 2017-06-07 2017-11-02 フィロゲン エスピーエー 炎症性腸疾患に関連する抗原
CN110997718B (zh) 2017-06-07 2023-11-10 菲洛根股份公司 血管内皮生长因子/抗纤连蛋白抗体融合蛋白
CN113811549A (zh) 2019-02-21 2021-12-17 Xencor股份有限公司 非靶向和靶向性il-10 fc融合蛋白
JP2022524018A (ja) * 2019-03-06 2022-04-27 デカ バイオサイエンシーズ， インコーポレイテッド Ｉｌ－１０バリアント分子ならびに炎症性疾患および腫瘍を処置する方法
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
CN116322785A (zh) 2020-07-20 2023-06-23 德卡生物科学公司 包含il-10的双细胞因子融合蛋白
US20230285585A1 (en) 2020-07-22 2023-09-14 Philogen S.P.A. Treatment of pulmonary hypertension
CN113480636B (zh) * 2021-06-23 2023-11-03 烟台科瑞斯生物技术有限责任公司 重组人纤连蛋白及其制备、活性测定和稳定性实验方法
EP4493210A1 (en) 2022-03-17 2025-01-22 Universitätsklinikum Jena Anti-ed-a antibodies for the treatment of pulmonary hypertension

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IT1217724B (it) 1988-05-26 1990-03-30 Ist Naz Ric Sul Cancro Anticorpo monoclonale specifico per una sequenza di fibronettina espressa in cellule trasformate ibridoma secernente tale anticorpo e impiego dell'anticorpo monoclonale per la diagnosi di tumori
US5420012A (en) * 1989-05-08 1995-05-30 Locus Genex Oy Method for the detection of reactive conditions
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
WO1992017604A1 (fr) * 1991-03-26 1992-10-15 Otsuka Pharmaceutical Factory, Inc. Anticorps monoclonal anti-eda
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US6492160B1 (en) 1991-05-15 2002-12-10 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5644033A (en) 1992-12-22 1997-07-01 Health Research, Inc. Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
AU6098994A (en) 1993-01-27 1994-08-15 Duke University Methods and agents for the diagnosis and treatment of rheumatoid arthritis
US6054312A (en) * 1997-08-29 2000-04-25 Selective Genetics, Inc. Receptor-mediated gene delivery using bacteriophage vectors
ATE439592T1 (de) 1998-12-10 2009-08-15 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
DK1719528T3 (da) 2000-02-24 2012-01-09 Philogen Spa Sammensætninger og fremgangsmåder til behandling af angiogenese i patologiske læsioner
WO2001076630A1 (en) * 2000-04-06 2001-10-18 Kyowa Hakko Kogyo Co., Ltd. Diagnostics and remedies for rheumatoid arthritis
WO2001083816A2 (en) 2000-05-04 2001-11-08 Philogen S.R.L. Method for detecting tumors
CA2421783A1 (en) * 2000-09-07 2002-03-14 Schering Aktiengesellschaft Receptor in the edb fibronectin domain
US6780594B2 (en) * 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
IT1317108B1 (it) 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
US20020187100A1 (en) 2000-12-21 2002-12-12 David Rizzieri Anti-tenascin monoclonal antibody therapy for lymphoma
EP1224943A1 (en) 2001-01-19 2002-07-24 Crucell Holland B.V. Fibronectin as a tumor marker detected by phage antibodies
US7585491B2 (en) 2002-12-13 2009-09-08 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
GB0209896D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
AU2003238284A1 (en) 2002-06-21 2004-01-06 Duke University Anti-tenascin antibody fragments and minibodies for treatment of lymphoma
WO2004032857A2 (en) * 2002-10-08 2004-04-22 Immunomedics, Inc. Antibody therapy
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
CA2523452A1 (en) 2003-04-22 2004-11-04 A & G Pharmaceutical, Inc. Cancer specific monoclonal antibodies
WO2005009366A2 (en) 2003-07-24 2005-02-03 Cornell Research Foundation, Inc. Restoring vascular function
EP1660519B1 (en) 2003-07-29 2014-05-14 Immunomedics, Inc. Conjugates comprising 2-[18F]fluoro-2-deoxy-D-glucose and a peptide molecule
CA2552590A1 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
US20060024757A1 (en) 2004-07-30 2006-02-02 Robert Hussa Detection of oncofetal fibronectin for selection of concepti
US7785591B2 (en) * 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
BRPI0517967B8 (pt) 2004-11-09 2021-05-25 Philogen Spa anticorpo isolado que liga-se a tenascina-c humana
EA013967B1 (ru) * 2004-12-23 2010-08-30 Мольмед Спа Продукт конъюгации
MX2007013875A (es) * 2005-05-11 2008-01-28 Philogen Spa Proteinas de fusion del anticuerpo l19 contra fibronectina ed-b e interlucina 12.
WO2007001940A2 (en) 2005-06-23 2007-01-04 Emory University Imaging agents
CA2650953A1 (en) 2006-05-03 2007-11-15 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody
BRPI0709787A2 (pt) * 2006-05-08 2011-03-29 Philogen Spa citocinas com anticorpos alvejados para terapia
EA036322B1 (ru) * 2007-04-02 2020-10-26 Филоджен С.П.А. Антитело, связывающееся с изоформой ed-a фибронектина, и его применение для лечения опухолевых метастазов
BRPI0812765B8 (pt) * 2007-07-25 2022-12-27 Philogen Spa Usos de um anticorpo que se liga à isoforma com domínio-a extra (ed-a) de fibronectina
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
PT3281952T (pt) 2007-10-30 2020-07-23 Philogen Spa Um antigénio associado a artrite reumatoide
AU2009336800A1 (en) 2009-01-07 2011-07-21 Philogen S.P.A. Cancer treatment
ES2549362T3 (es) 2009-01-07 2015-10-27 Philogen S.P.A. Antígenos asociados a endometriosis
BR112013007160A2 (pt) 2010-09-29 2016-06-14 Philogen Spa ligante tiazolidina para a conjugação de fármacos a anticorpos
ES2706428T3 (es) 2011-07-27 2019-03-28 Philogen Spa Inmunoconjugado de IL-12
PT2903629T (pt) 2012-10-03 2019-09-10 Philogen Spa Conjugado de anticorpo para utilização no tratamento de uma doença inflamatória do intestino
WO2014174105A1 (en) 2013-04-25 2014-10-30 Philochem Ag Antibody-drug conjugates
AU2014257906A1 (en) 2013-04-26 2015-12-10 Philogen S.P.A. IL4 conjugated to antibodies against extracellular matrix components
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
ES2646228T3 (es) 2017-12-12
BRPI0818272B8 (pt) 2021-05-25
EP2209805A1 (en) 2010-07-28
US20190352384A1 (en) 2019-11-21
BRPI0818272B1 (pt) 2021-01-12
JP6198703B2 (ja) 2017-09-20
KR20100101587A (ko) 2010-09-17
DK3281952T3 (da) 2020-08-03
PL2209805T3 (pl) 2018-01-31
EP3281952A1 (en) 2018-02-14
EP2209805B1 (en) 2017-09-06
US20100260707A1 (en) 2010-10-14
AU2008317941B2 (en) 2015-01-22
RU2649368C2 (ru) 2018-04-02
WO2009056268A1 (en) 2009-05-07
DK2209805T3 (en) 2017-10-16
SI3281952T1 (sl) 2020-09-30
CA2704296C (en) 2017-08-22
BRPI0818272A2 (pt) 2015-04-14
RU2013115891A (ru) 2014-10-20
JP2013040183A (ja) 2013-02-28
KR101608544B1 (ko) 2016-04-01
JP5106635B2 (ja) 2012-12-26
US10385121B2 (en) 2019-08-20
CA2704296A1 (en) 2009-05-07
MX2010004726A (es) 2010-05-20
US20170298122A1 (en) 2017-10-19
KR102002739B1 (ko) 2019-07-23
JP6154594B2 (ja) 2017-06-28
PT2209805T (pt) 2017-11-14
CN101918443B (zh) 2013-07-17
PT3281952T (pt) 2020-07-23
CN101918443A (zh) 2010-12-15
US8222377B2 (en) 2012-07-17
ES2807753T3 (es) 2021-02-24
KR20180027640A (ko) 2018-03-14
KR101836968B1 (ko) 2018-03-12
CN103396483A (zh) 2013-11-20
AU2008317941A1 (en) 2009-05-07
US9556257B2 (en) 2017-01-31
JP2011502137A (ja) 2011-01-20
JP2015091799A (ja) 2015-05-14
EP3281952B1 (en) 2020-06-24
HUE037036T2 (hu) 2018-08-28
RU2010121874A (ru) 2011-12-10
SI2209805T1 (sl) 2017-11-30
EP3783019A1 (en) 2021-02-24
RU2486198C2 (ru) 2013-06-27
CN103396483B (zh) 2016-11-23
HUE050038T2 (hu) 2020-11-30
KR20160039305A (ko) 2016-04-08
US20120244114A1 (en) 2012-09-27
PL3281952T3 (pl) 2020-11-16

Similar Documents

Publication Publication Date Title
NO2209805T3 (cg-RX-API-DMAC7.html)
CN300728877S (zh) 秋千椅(三人座特斯林)
CN300727581S (zh) 收录放音机(gh-642)
CN300788801S (zh) 木梳
CN300788164S (zh) 转移印花纸(07-7)
CN300781752S (zh) 马达
CN300768311S (zh) 床(603)
CN300762794S (zh) 宠物玩具(狗咬枝)
CN300751756S (zh) 面料(nh7005)
CN300740568S (zh) 床
CN300731579S (zh) 视听柜(靓点1280)
CN300727535S (zh) 工业设备按钮
CN300727525S (zh) 漏电断路器(tgb7l-40)
CN300731180S (zh) 手把(Am9158)
CN300730915S (zh) 摩托车号牌灯
CN300805707S (zh) 视听柜(b-2500)
CN300730889S (zh) 贴片式led(28103)
CN300730885S (zh) 灯(仰头鹿2)
CN300727231S (zh) 磁开关探测器
CN300727182S (zh) 包装袋(茶满多生物有机肥)
CN300726954S (zh) 包装盒(黄金搭档女士型)
CN300730803S (zh) 蜡烛(71)
CN300730548S (zh) 分体壁挂式室内机(np)
CN300730219S (zh) 监控摄像机
CN300730187S (zh) 工业电熨斗底座(hg-680)